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BACKGROUND: The model of pleurisy induced by carra-
geenan exhibits a biphasic response (4 and 48h) and
permits the quantification of exudate, cell migration
and certain enzymes such as myeloperoxidase (MPO)
and adenosine-deaminase (ADA) that are markers of
activated leukocytes.
Aims:  The  present  study  evaluates  whether  there
exists, in the pleurisy model, a significant inhibition
of  ADA  and  MPO  enzymes,  leukocyte  kinetics  and
other  markers  of  inflammation  [nitric  oxide  (NO)
levels, exudation] caused by methotrexate treatment
by the intraperitoneal (i.p.) route.
Methods: The pleurisy was induced by carrageenan
(1%) in mice, and the parameters were analyzed 4 and
48h after.
Results:  After  the  induction  of  inflammation  (4h),
methotrexate  (20mg/kg,  i.p.,  24h  before  pleurisy
induction)  inhibited  the  leukocyte  infiltration  (p <
0.05), NO levels and MPO activity (p < 0.01), but not
ADA activity and fluid leakage (p > 0.05). Regarding
the  second  phase  of  pleurisy  (48h),  methotrexate
(40mg/kg, i.p., 0.5h before pleurisy induction) inhib-
ited the leukocyte infiltration (p < 0.05), fluid leakage,
NO levels (p < 0.01), and ADA and MPO activity (p <
0.05).
Conclusions:  These  findings  support  the  evidence
that the acute administration of methotrexate has an
important systemic anti-inflammatory activity in the
studied inflammatory model. This effect was due to a
significant inhibition on both neutrophil and mono-
nuclear cells, being less marked in relation to exuda-
tion 48h after. In relation to the enzymes studied and
to NO levels, the findings support the evidence that
methotrexate inhibits both enzymes (MPO and ADA)
from leukocytes at the site of injury, thus reflecting
the activation of both neutrophils and lymphocytes,
respectively.  Furthermore,  the  inhibiting  effect  on
NO in both phases of pleurisy induced by carragee-
nan (4 and 48h) indicates that methotrexate acts on
constitutive and/or inducible NO synthases by means
of different cells of the pleural cavity.
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Introduction
Methotrexate,  a  folate  antagonist,  is  a  potent  anti-
inflammatory agent.1 Because of its efficiency as an
immunosuppressive agent, which at low doses does
not affect cellular proliferation, it has been used in the
treatment of rheumatoid arthritis.2 More recently, it
has  also  been  used  in  post-transplant  therapy  to
successfully  reverse recalcitrant rejection in cardiac
transplant patients.3,4
The mechanisms by  which methotrexate inhibits
both  acute and chronic inflammation  remains  con-
troversial. Evidence indicates that methotrexate treat-
ment  decreases neutrophil–endothelial adhesion in
vitro by  modulating  the  expression  of  integrins.
Furthermore,  this  drug  also  suppresses  neutrophil
accumulation  and  exudation  in  the  reverse passive
Arthus reaction of rat dorsal skin, nitric oxide (NO)
production by inducible nitric oxide synthase (iNOS)
in murine lung epithelial cells in vitro, and decrease
of the prostaglandin E2 release in the cultured human
rheumatoid  synoviocytes,5–7 among  others.  It  has
been proposed that these effects are probably medi-
ated, in part, by adenosine release from endothelial
cells, followed by adenosine receptor occupancy on
macrophages and lymphocytes, since it is reversed by
adenosine-deaminase  (ADA).8,9 The  adenosine
released  at  inflamed  sites  interacts  with  specific
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inflammation and tissue injury.
In the present study, we evaluated the acute anti-
inflammatory effects of methrotrexate in the inflam-
matory model of mouse pleurisy induced by carragee-
nan.  The  inflammatory  profile  of  this  model  is
characterized  by  an  early  (4h)  and  a  late  (48h)
inflammatory phases in response to the carrageenan
challenge,  where  several  mediators  [such  as  hista-
mine, bradykinin, prostaglandins, platelet-acether fac-
tor, myeloperoxidase (MPO), ADA and leukotrienes]
are involved.10–12 In addition to the evaluation of both
the  early  (4h)  and  late  (48h)  amounts  of  both
leukocyte  migrations  and  leakage influxes  into  the
pleural cavity, nitrate/nitrite concentrations that indi-
rectly  reflect  NO  production13 and  MPO  and ADA
activities were also measured in the pleural fluid, and
compared with those found in a non-treated mouse.
Methods
Animals
Non-fasted adult Swiss mice of both sexes (18–25g),
aged  2  months,  were  used  throughout  the  experi-
ments. They were housed in accordance with institu-
tional  animal  care (temperature  21  ± 2°C, under  a
light/dark  cycle  of  12h)  and  were  freely  fed  on
standard rodent chow and water.
Two groups of animals were studied: pre-treated,
and untreated with methotrexate prior to the induc-
tion of pleurisy with carrageenan. In parallel, two or
three animals that had received an injection of either
sterile saline by the intrapleural route or methotrexate
by the intraperitoneal (i.p.) route were included in all
experimental groups (results not shown). In prelimi-
nary experiments (results not shown), several doses
of  methotrexate and different  intervals of  pre-treat-
ment were tested. Based on these results, the period
0.5h prior to carrageenan injection was chosen for
use in the experiments described.
In a first set of experiments, animals were treated
0.5h before pleurisy induction with different doses of
methotrexate (1–40mg/kg,  i.p.)  and  the  inflamma-
tory  parameters  were  analyzed  4  and  48h  after
carrageenan injection. In other experiments, animals
were pre-treated (0.5–48h) with methotrexate (20 or
40mg/kg,  i.p.)  and  the  same  inflammatory  para-
meters  were  evaluated  4  and  48h  after  pleurisy
induction.
Experimental design
Induction and analysis of pleurisy
As previously reported,11,14 the mouse pleurisy was
induced by a single intrapleural injection of 0.1ml of
sterile saline plus carrageenan (1%). Since the pleurisy
caused by carrageenan exhibits a biphasic response (4
and 48h), both interval points were chosen to analyze
the studied parameters.
After killing the animals with an overdose of ether,
the  thorax was opened and the  pleural  cavity was
washed  with  1.0ml  of  sterile  phosphate-buffered
saline (PBS) (pH 7.6; composition, 137mmol of NaCl
and 2.7mmol of KCl) containing heparin (20IU/ml).
Several samples of the pleural lavage were collected for
further determination of  both MPO  and ADA  activ-
ities,15,16 exudation levels and NO concentrations,13 as
well as total and differential leukocyte contents. Total
leukocyte counts were performed  on an automatic
counting machine (Beckman Coulter, Brea, California,
USA), whereas cytospin preparations of pleural wash-
ing were stained with May–Grunwald–Giemsa for the
differential count of leukocytes, which was performed
under  an  immersion  objective.  According  to  the
experimental protocol, another two groups of animals
that had been injected 1h previously with a solution of
Evans blue dye (25mg/kg, i.v.), in order to evaluate the
degree of exudation in the pleural cavity (Elisa-Reader;
Organon, Roseland, New Jersey, USA) at 600nm, were
included  in  both  the  treated  and  the  non-treated
methotrexate groups.
Determination of nitrate/nitrite concentration
NO was measured as its breakdown product of nitrite
(NO2
–) and nitrate (NO3
–) using the Griess method.15
Samples of the pleural lavage obtained from control
and treated animals that did not receive Evans blue
dye injection were separated and stocked at –70°C.
On  the  day  of  the  experiments,  the  samples  were
thawed and de-proteinized by the addition of 6 mM
sodium  hydroxide  and  0.6%  of  zinc  sulfate.  After-
wards, 250ml of pleural lavage was diluted in 30ml of
ammonium format, 30ml of hydrate disodium hydro-
gen phosphate-12 and 30ml of Escherichia coli (EC
ATCC 25922;  diluted 1  :  7  in  PBS),  and were then
incubated for 2h at 37°C. After centrifugation at 50 ´
g for 5min, 250ml of the supernatant was transferred
to  cuvettes  and  the  same  volume  of  fresh  Griess
reagent [5% (vol/vol) of H3PO4, 1% of sulfanilic acid
and  0.1%  of  N-(1-naphythyl)  ethylenediamine]  was
added and incubated for 10min at room temperature.
The reaction of NO2
– with this reagent produced a
pink color, which was quantified at 543nm against
standards (0–150mM) on an Elisa-reader (Organon).
Enzymatic assays
In-house assays of both MPO and ADA were employed
according to the methods developed by RAO et al.16
and Giusti and Galanti.17 Using conventional reagents,
each  enzymatic  concentration  was  estimated  by
means of colorimetric measurements (absorbances of
450  and 630nm,  respectively)  in  an Organon, USA
spectrophotometer  (U-2001;  Organon,  USA).  One
unit of MPO is defined as the activity of the enzyme
that  oxides  one  molecule  of  H2O2 per  minute,
E. M. Dalmarco et al.
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FIG. 1. Effect of methotrexate on early (4h) or late (48h) phases of the mouse model of pleurisy induced by carrageenan (1%).
(A) Effect of methotrexate (20mg/kg, i.p., 24h prior) on the early (4h) phase of inflammatory response upon the leukocyte
migration. (B) Effect of methotrexate (40mg/kg, i.p., 0.5h prior) on the late (48h) phase of inflammatory process. Insets: Effect
of methotrexate upon exudation levels under the same conditions. C, Animals treated only with carrageenan. Each group
represents the mean of six to 10 animals, bars represent the SEM. * p < 0.05, ** p < 0.01.whereas one unit of ADA is equivalent to the amount
of enzyme required to release 1 millimole of ammonia
per minute. Results are expressed as milli-units  per
microliter (MPO) and units per liter (ADA).
MPO assay
Standard  samples  with  different  concentrations  of
MPO  (from  human  neutrophils)  (M6908;  Sigma,  St
Louis, MO, USA) were prepared in order to obtain a
standard  curve  in  the  range  of  0.07–140mU/ml.
Pleural aliquots (40ml) and standards were transferred
to cuvettes and the reaction was initiated with the
addition  of  360ml  of  assay  buffer  (0.167mg/ml  of
o-dianisidine 2HCl and 0.0005% H2O2). The reaction
was stopped with 1% sodium azide. Afterwards, the
samples  were  centrifuged  at  50 ´ g for  5min,  the
supernatants were separated, and the rates of changes
in  absorbancy  were  determined.  MPO  activity  was
estimated by  interpolation from the standard curve
described earlier. Samples in which the levels of MPO
were above the higher limit of detection (140mU/ml)
were diluted (two-fold to five-fold) and the concentra-
tions  were  corrected  for  the  two-fold  to  five-fold
dilution,  whereas  results  below  the  lower  limit  of
detection were expressed as 0.7mU/ml.
ADA assay
Initially,  standard  samples  (final  volume  of  500ml)
with  different  volume  concentrations  of  NaH-
2PO4·H2O  (35 mM),  Na2HPO4·H2O  (15 mM)  and
NH3SO4 (15 mM) were prepared to obtain a standard
curve in the range of 10–50U/l. Pleural fluid samples
(20ml) were transferred to cuvettes and the reaction
was initiated by the addition of adenosine phosphate-
buffered solution [pH 6.5, 500ml; composition, NaH-
2PO4·H2O  (35 mM),  Na2HPO4·12H2O  (15 mM)  and
adenosine (0.5 mM)]. After incubation for 1h at 37°C,
the reaction was halted with the addition of a solution
(1000 ml)  of  phenol  (1 mM)  and  nitroprussiate
(0.17 mM),  plus  alkaline  buffer  (1000ml;  11 mM
NaOCl). This solution (final volume of 2000ml) was
also added to the cuvettes with the different standard
samples. Afterwards, the rate of change in absorbancy
was determined. The ADA activity was estimated by
interpolation  from  the  standard  curve  described
earlier.  The  reagents  were  stable  at  2–8°C  for  1
month.
Drugs
The  following  drugs  were  purchased  as  indicated:
Evans  Blue  dye,  carrageenan  (degree  IV),  sodium
azide, o-dianisidine 2HCl (3,39-dimethoxybenzidine),
human polymorphonuclear leukocyte MPO (Sigma),
methotrexate (Wyeth, S˜ ao Paulo, SP, Brazil), heparin
(Liquemine®;  Roche,  S˜ ao  Paulo,  SP,  Brazil),  NaH-
2PO4·H2O,  Na2HPO4·12H2O,  NH3SO4,  nitroprussiate
(Montedison, S˜ ao Paulo, SP, Brazil), adenosine (Fluka,
Ronkonkoma, NY, USA), alkaline buffer (Merck, S˜ ao
Paulo,  SP,  Brazil),  phenol  (Biotech,  S˜ ao  Paulo,  SP,
Brazil). NaCl (0.9%) and May–Grunwald–Giemsa dye
were from different commercial sources. PBS (Merck)
(pH 7.6; composition, 137mmol of NaCl, 2.7mmol of
KCl,  and  10 mM  phosphate  buffer  salts)  was  pre-
viously prepared and maintained in the refrigerator.
All  drugs  were  kept  in  siliconized  plastic  tubes  at
–20°C. On the day of the experiments, the drugs were
diluted to the desired concentration with sterile saline
solution at room temperature.
Statistical analysis
Data  is  reported  as  the  mean  ±  SEM.  Statistical
differences  between  groups  were  determined  by
analysis of variance and complemented with Dunnet’s
and/or  Student’s  tests.  p <  0.05  was  considered
indicative of significance.
Results
Figures 1A and 1B show that pre-treatment (0.5 and
24h, respectively) of the animals with different doses
of  methotrexate  was  associated  with  a  significant
decrease of  leukocyte  migration  either at  the  early
(4h) or the late (48h) phases of the studied inflamma-
tory  process. This  inhibitory  effect  was  not  dose
dependent. By contrast, methotrexate did not inhibit
fluid leakage that occurs in the early phase (4h) of
this  pleurisy  model,  but  did  at  48h  (Fig.  1A,B,
inset).
Analysis of cell migration in the early (4h) phase of
this inflammatory reaction demonstrated that metho-
trexate caused a bimodal profile of the time-course
kinetics  (20mg/kg,  i.p.,  0.5–24h  prior  to  pleurisy
induction) (Fig. 2). As shown, according to the period
of time chosen to administer this drug, an inhibitory
effect was observed when it was given 0.5 or 24–48h
before, but not when it was given 1–12h before. The
degree  of  inhibition  was  directly  related with  neu-
trophil influx (Fig. 2, inset).
Although the inhibitory effect induced by metho-
trexate  (1–40mg/kg,  i.p.)  was  not  dose  related,
preliminary experiments (data not shown) had dem-
onstrated that doses of 1–20mg were ineffective in
inhibiting nitrate/nitrite concentrations and MPO and
ADA activities in the pleural leakage. Thus, the doses
of 20 and 40mg/kg, i.p., of methotrexate and the pre-
treatment times of either 0.5 or 24h were chosen to
analyze nitrate/nitrite concentrations and also MPO
and ADA activities in the pleural lavage (4 and 48h
after  pleurisy  induction,  respectively).  Analysis  of
these parameters 4h after pleurisy induction (Fig. 3)
shows  that  methotrexate  (20mg/kg,  i.p.),  when
administered  either  0.5  or  24h  before,  caused  a
marked reduction of  both nitrate/nitrite levels (Fig.
3A) and of MPO activity (Fig.  3B). Under the same
E. M. Dalmarco et al.
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activity was detected when methotrexate was admin-
istered  0.5h  before,  but  not  24h  before,  pleurisy
induction (Fig. 3C).
When  the  same  inflammatory  indices  were  ana-
lyzed 48h after pleurisy induction (Fig. 4), all studied
parameters  were  significantly  reduced.  As  shown,
methotrexate  (40mg/kg,  i.p.)  caused  a  significant
decrease in the levels of nitrate/nitrite (Fig. 4A) and of
both MPO (Fig. 4B) and ADA activities (Fig. 4C).
Discussion
The present data show that methotrexate is able to
reduce the two pools of leukocyte populations that
migrate to the pleural space at distinct periods of time
(4  and 48h)  after the induction  of  mouse pleurisy
with  carrageenan. Although  this  drug  was  acutely
administered to the animals, it presented bimodal and
long-lasting profiles characterized by two inhibitory
effects  that  occurred  early  and  late  (pre-treatment
times of 0.5 and 24h, respectively). This inhibition of
cell influx into the pleural cavity was associated with
a marked reduction of both MPO activity and nitrate/
nitrite  concentrations.  ADA  activity  that  was  sig-
nificantly raised early after the induction of pleurisy
(4h) presented a significant fall 48h later.
It is interesting that the inhibitory effects induced
by methotrexate upon cell migration in this model of
pleurisy were not dose dependent. Furthermore, the
inhibitory  doses  of  this  agent  upon  the  studied
inflammatory parameters clearly differed according to
the  studied  variables.  According  to  our  protocol,
doses  of  1  and  10mg/kg  effectively  inhibit  cell
migration  4  and  48h  after  pleurisy  induction.  Fur-
thermore, exudation of the early phase (4h), but not
of  the  late  (48h)  phase,  were  not  inhibited.  In
addition, only higher doses of methotrexate (20 and
40mg/kg,  i.p.)  were  effective  in  inhibiting  other
inflammatory parameters such as MPO activity and
nitrite/nitrate  levels.  These  findings  suggest  that
certainly  there  is  a  narrow  range  between  anti-
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FIG. 2. Effect of methotrexate (20mg/kg, i.p.) administered 05–48h before carrageenan administration, on the early leukocyte
migration (4h) in the mouse pleural cavity. Inset: Effects of this drug on both neutrophils and mononuclears. C, Animals treated
only with carrageenan. Each group represents the mean of six to 10 animals, vertical bars represent the SEM. ** p < 0.01.E. M. Dalmarco et al.
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FIG. 3. Effect of methotrexate (20mg/kg, i.p.) on (A) nitrate/
nitrite levels, (B) myeloperoxidase and (C) adenosine-deami-
nase  activities.  All  parameters  were  measured  4h  after
pleurisy induction. C,  Animals treated only with carragee-
nan. Each group represents the mean of six to 10 animals,
vertical bars represent the SEM. * p < 0.05, ** p < 0.01.
FIG. 4. Effect of methotrexate (40mg/kg, i.p.) on (A) nitrate/
nitrite levels, (B) myeloperoxidase and (C) adenosine-deami-
nase  activities.  All  parameters  were  measured  48h  after
pleurisy induction. C,  Animals treated only with carragee-
nan. Each group represents the mean of six to 10 animals,
vertical bars represent the SEM. * p < 0.05, ** p < 0.01.inflammatory and immunossupressive  effects attrib-
uted to this drug.
MPO,  ADA  and  products  of  pathways  that  are
mediated by  iNOS have been widely  recognized as
powerful  pathways implicated in several aspects of
the inflammatory cascade including,  among others,
plasma exudation and cell  migration.18 In  this con-
text, we have previously  demonstrated that,  in  the
studied model of inflammation, the levels of nitrite/
nitrate  are  significantly  elevated  at  4  and  48h,
whereas increased levels of MPO are only observed in
the  early  phase.12,14 The  mechanisms  by  which
methotrexate inhibits the inflammatory process have
been  studied  in  several  models  of  inflammation
where  the  production  of  NO  via  iNOS  inductive
pathways,  among  others,  has  been  character-
ized.5,19,20Thus, it was demonstrated that methotrex-
ate caused a dose- and time-dependent inhibition of
nitrate/nitrite  produced  by  murine  lung  epithelial
cells in vitro.5 Other studies, however, have shown
that methotrexate does not affect NO production via
iNOS induced in chondrocytes from either humans or
rabbits.20,21 The findings of the present work indicat-
ing that methotrexate caused a significant reduction
in nitrite/nitrate levels in both phases (4 and 48h) of
this inflammatory reaction add support to the hypoth-
esis that methotrexate’s anti-inflammatory effects in
this model may also be occurring via inhibition of NO
generation.
Another pathway for this drug’s anti-inflammatory
effect is via inhibition of neutrophil migration to the
site of inflammation due to its inhibitory effect upon
cell–cell adhesion; namely, the expression of CD11b,
CD18 molecules.22 Since MPO activity is an indirect
marker of activated neutrophil, the low MPO activity
following methotrexate treatment could be explained
by the inhibition of neutrophil influx. Based on these
results, it is possible that methotrexate’s inhibition of
neutrophil influx may be linked with a decrease of
adhesion  molecules  that  facilitates  such  neutrophil
influxes.
The  effects  of  methotrexate  upon  ADA  activity
were also evaluated in this model. It is well demon-
strated that this drug may increase the intracellular
concentration of an enzyme (AICAR transformylase)
required for de novo purine synthesis.23This results in
an increase in the release of adenosine, a potent anti-
inflammatory autacoid, at the site of inflammation.24
The subsequent interaction of adenosine with adeno-
sine type 2 receptors may inhibit, among others, the
expression of CD11b/CD18 molecules in leukocytes
that  promote  and  facilitate  cell  migration.25,26 To
validate these findings, several in vitro studies have
shown that ADA is able to suppress the effects of the
released  adenosine.  In  the  present  work,  pre-treat-
ment  of  the  animals  caused  a  reduction  of  the
mononuclear  cellular  pool  in  association  with  a
marked reduction of ADA activity. According to these
results, the hypothesis that a decrease in ADA activity
could favor the action of adenosine that was released
by  methotrexate  at  the  site  of  the  inflammatory
reaction cannot be discarded. Otherwise, the fact that
ADA  activity  remained  elevated  4h  after  pleurisy
induction when methotrexate was administered 0.5h
before, but not 24h before, indicates that methotrex-
ate  elicits  its  anti-inflammatory  effects  via  other
mediator pathways besides adenosine.
In summary,  the present work presents evidence
that the inhibitory effect of methotrexate upon both
neutrophil and mononuclear cells is associated with a
parallel  decrease  of  NO  production  and  of  MPO
activity. The results regarding the adenosine activity
indirectly show that different mechanisms other than
a direct action upon adenosine release contribute to
this  anti-inflammatory  effect.  Taken  together,  the
experimental  data  indicates  that  the  anti-inflamma-
tory  effects  induced  by  methotrexate  occurs  via
different mechanisms and is possibly dependent on
the model of inflammation.
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